Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice
Open Access
- 17 August 2006
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 14 (1) , 20-29
- https://doi.org/10.1038/sj.gt.3302840
Abstract
Vaccinia virus has been shown to efficiently infect tumor cells. Therefore, vaccinia virus represents a potentially safe and effective antitumor agent against ovarian cancer. Here, we assessed the ability of vaccinia virus to preferentially infect and control both human and murine ovarian tumors in vivo. We used the non-invasive luminescence imaging system to monitor the infection and suppression of ovarian tumors by vaccinia in live mice. Our data indicated that vaccinia was able to effectively infect and kill both human and murine ovarian tumors. Vaccinia virus administered to mice intraperitoneally was specifically targeted to the murine or human ovarian tumors and led to antitumor responses. These findings suggest that vaccinia virus is capable of selectively targeting and controlling ovarian tumors. Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers.Keywords
This publication has 25 references indexed in Scilit:
- Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing CarcinomasJournal of Clinical Oncology, 2005
- Fighting Cancer with Vaccinia Virus: Teaching New Tricks to an Old DogMolecular Therapy, 2005
- Subcutaneous Administration of a Recombinant Vaccinia Virus Vaccine Expressing Multiple Envelopes of HIV-1European Journal of Clinical Microbiology & Infectious Diseases, 2004
- Systemic tumor targeting and killing by Sindbis viral vectorsNature Biotechnology, 2003
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancerThe Journal of Gene Medicine, 2003
- Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene TherapyJournal of Virology, 2001
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutantCancer Gene Therapy, 2000
- Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanomaCancer Gene Therapy, 1999
- Selection of Therapy for Stage III Breast CancerSurgical Clinics of North America, 1990